And not to overlook the joint collaboration with Cambridge...

And not to overlook the joint collaboration with Cambridge University, there are no less than six deal discussions underway in relation to - Phenomica target identification (ID) & validation.

At first I missed this piece of detail. Phenomica, however, could be an exciting development as it pursues 'target discovery against high value disease pathways'. Six deal discussions indicate a high level of international interest in the project. Bringing together the phylomer libraries, the scientific expertise of Cambridge University which I understand is highly regarded and potentially the money and methodology of Big Pharma.